Tag Archives: Intralesional Injection

Business, Finance, Occupation & Industry

PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Resp

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

PV-10 Data Presented by Moffitt Cancer Center Researchers Examines Induction of Systemic Immune Response in Multiple Tumor Types

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced details of a poster presentation on the induction of a systemic immune response with intralesional (IL) PV-10 by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.

The poster entitled, “Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma,” was presented by Shari Pilon-Thomas, Ph.D., Immunology Program, Moffitt Cancer Center.

Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases (i.e., bystander lesions).

The Moffitt study examined the immunologic mechanism of PV-10 treatment in murine models of breast cancer and melanoma to determine how IL PV-10 therapy induces the systemic anti-tumor immune response apparent in bystander responses in clinical trial participants. In the current work, IL injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions in the MT-901 breast cancer model, with a significant increase in survival in mice treated with IL PV-10 versus those treated with IL saline. In a synchronous flank tumor/lung metastasis model, there was a significant reduction in lung metastases and subcutaneous tumor size in mice treated with IL PV-10 versus those treated with IL saline. Injection of PV-10 into the opposite, non-tumor bearing flank, did not affect the size of subcutaneous lesions nor the number of lung metastases. Splenocytes harvested from PV-10-treated mice exhibited tumor-specific enhancement of interferon-gamma production and cytotoxicity against the treated cell line, along with adoptive transfer of immunity upon implantation in naïve mice. A copy of the poster is available at the following link:

http://www.pvct.com/publications/SPTAACR2013-Final.pdf

Dr. Pilon-Thomas commented, “The findings of this study confirmed not only that PV-10 induces tumor-specific immunity after a single treatment with IL-PV-10 in multiple tumor types, but that the ablative process is critical for this in situ stimulation of the immune system. The data also show that T cells play a critical role in this response. We feel this is a promising direction for additional

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

PV-10 Immunology Data Presented by Moffit Cancer Center Researchers at the American Association for Cancer Research Annual Meeting

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that a poster presentation detailing the induction of tumor specific immunity after intralesional PV-10 treatment was presented by researchers from the Moffitt Cancer Center at the American Association for Cancer Research Annual Meeting in Washington, DC.

The poster presentation, based on Abstract #1248 entitled, “Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma,” was authored by Shari Pilon-Thomas1, Amy Weber1, Krithika Kodumudi1, Lisa Kuhn1, Paul Toomey2 and Amod A. Sarnaik1 of 1Moffitt Cancer Center, Tampa, FL and the 2University of South Florida, Tampa, FL.

Provectus’s PV-10, a 10% solution of Rose Bengal, is currently being examined as a novel cancer therapeutic. It is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. In melanoma patients, intralesional (IL) injection of PV-10 has led to regression of injected lesions as well as distant metastases.

The Moffitt Cancer Center investigational study, which examined the potential immune mechanism of PV-10 treatment in murine models of breast cancer and melanoma, demonstrated that injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions, with a significant increase in survival in mice treated with PV-10. In related experiments using a melanoma lung metastasis model, mice that received PV-10 treatment of a cutaneous tumor had markedly fewer lung metastases compared to controls receiving saline. The poster was presented by Shari Pilon-Thomas, Ph.D, Immunology Program, Moffitt Cancer Center.

Dr. Pilon-Thomas commented, “We believe our findings are meaningful because they confirm the induction of tumor-specific immunity after single treatment with IL–PV-10 in multiple tumor types. Our data show that T cells play a crucial roll in this response, and we are continuing our work to further elucidate the mechanisms that occur following PV-10 treatment.”

Dr. Amod Sarnaik observed, “The systemic response to intralesional PV-10 treatment observed in murine models was sufficiently compelling to warrant further clinical investigation. We look forward to additional insights from our current investigational study of the immune mechanism of PV-10 ablation in cutaneous melanoma patients.”

Additional details on the immunological mechanism of action of PV-10 being presented during the AACR Annual Meeting poster session will be forthcoming. Abstract #1248 can be accessed at the following link:

…read more

Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual Meet

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Immunology Data on PV-10 to Be Presented at the American Association for Cancer Research Annual Meeting

— Moffitt Cancer Center Poster Presentation on April 8, 2013 —

KNOXVILLE, Tenn.–(BUSINESS WIRE)– Provectus Pharmaceuticals, Inc. (OTCQB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that mechanism data on the induction of tumor specific immunity after intralesional PV-10 treatment will be presented by researchers from Moffitt Cancer Center and the University of South Florida in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC.

The poster, based upon abstract #1248 entitled “Intralesional Injection with PV-10 Induces a Systemic Anti-tumor Immune Response in Murine Models of Breast Cancer and Melanoma,” authored by Shari A. Pilon-Thomas, Amy Weber, Krithika Kodumudi, Lisa Kuhn, Paul Toomey, Amod Sarnaik, will be presented on April 8, 2013, from 1:00 p.m. – 5:00 p.m. in Hall A-C, Poster Section 5, Poster #28.

Craig Dees, Ph.D., CEO of Provectus Pharmaceuticals said, “The researchers at Moffitt are providing valuable insights into how PV-10 harnesses the immune system in specific response to the injected tumor. Although the study being presented was done in murine models of melanoma and breast cancer, the currently open clinical trial at Moffitt is designed to investigate this mechanism in melanoma patients. We are pleased to enhance our understanding of intralesional PV-10 and its potential to produce a systemic benefit in cancer patients.”

PV-10 is Provectus Pharmaceuticals‘ novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects.

About the American Association for Cancer Research

The AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research. Its reputation for scientific breadth and excellence attract the premier researchers in the field. The programs and services of the AACR foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.

About Provectus Pharmaceuticals, Inc.

Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy …read more
Source: FULL ARTICLE at DailyFinance